

سامية محمد مصطفى



شبكة المعلومات الجامعية

بسم الله الرحمن الرحيم



سامية محمد مصطفى



شبكة المعلومات الجامعية



شبكة المعلومات الجامعية التوثيق الالكتروني والميكرو فيلم



سامية محمد مصطفى



شبكة المعلومات الجامعية

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



سامية محمد مصطفى



شبكة المعلومات الجامعية



بعض الوثائق الأصلية تالفة



سامية محمد مصطفى



شبكة المعلومات الجامعية



بالرسالة صفحات
لم ترد بالأصل





Surgical Aspects of Suprarenal Tumours

(ESSAY)

Submitted in Partial Fulfillment For The M.Sc.
Degree In Surgery

By

Emad Tawadros Boshra

Supervised by

Dr. Gamal Abdel Hamid

Professor of General Surgery
Faculty of Medicine,
Assiut University

Dr. Ahmed Abdel Hamid

Ass. Professor of General Surgery
Faculty of Medicine,
Assiut University

**Faculty of Medicine – Assiut University
2000.**

B

12129

Acknowledgments

I would like to express my sincere thanks and deep gratitude to Professor Dr. Gamal Abd El -hameed, Professor of General Surgery, Assiut University for choosing the subject of this study for me, for giving me a lot of his time, for guiding me throughout this study, word by word, and for his fatherly kindness and support.

I am also deeply grateful to Ass. Professor Dr. Ahmed Abd El-hameed, Ass. Professor of General Surgery, Assiut University for helping me out with this study, for his continuous help and encouragement, for giving me a lot of his time and for his much support.

I would like also to thank Miss Miral Alfay Fayed for typing the manuscript and keeping up with me while making many corrections and reprints.

Last, but not least, I would like to thank my family, especially my wife for her sacrifice and continuous encouragement and forgiving me when I was much preoccupied with this work.

To

My *F*amily

(My Mother, My Father, My Brother)

and

My *W*ife

Table of Contents

Introduction	1
---------------------	----------

Chapter One	
Embryology and Anatomy of the Adrenal Glands	
[A] Embryology of the Adrenal glands	4
I. Embryology of the Adrenal Cortex	4
II. Embryology of the Adrenal Medulla	6
[B] Gross Anatomy of the Adrenal Glands	7
[C] Microscopic Anatomy	15

Chapter Two	
Physiology of the Adrenal Glands	
[A] Adrenal Cortex	17
[B] Adrenal Medulla	23

Chapter Three	
Tumours of the Adrenal Cortex	
[A] Adrenal Adenoma and Carcinoma	28
I. General Considerations	28
II. Pathology	28
III. Genetics and Tumourigenesis of Adrenal Cortical Neoplasms	41
IV. Staging of Adrenocortical Carcinoma	42
V. Clinical Presentation of Adrenocortical Neoplasms	43
VI. Laboratory Diagnosis of Adrenocortical Tumours	52
VII. Treatment of Adrenocortical Neoplasms	62
VIII. Prognosis of Adrenocortical Neoplasms	67
IX. Adrenocortical Neoplasia in Children	69
[B] Other Tumours of the Adrenal Cortex	71
I. Stromal Tumours	71
II. Adrenal Myelolipomas	71
III. Adrenal Metastasis	73

Chapter Four

Tumours of the Adrenal Medulla

[A] Phaeochromocytoma	75
I. Pathology	75
II. Clinical Picture of Phaeochromocytoma	86
III. Laboratory Diagnosis of Phaeochromocytoma	90
IV. Treatment of Phaeochromocytoma	94
[B] Neuroblastoma	106
I. General Considerations	106
II. Pathology	107
III. Clinical Picture of Neuroblastoma	114
IV. Staging of Neuroblastoma	118
V. Diagnosis and Differential Diagnosis of Neuroblastoma	122
VI. Prognosis of Neuroblastoma	125
VII. Special Categories of Neuroblastoma	133
VIII. Mass Screening for Neuroblastoma	138
IX. Treatment of Neuroblastoma	140

Chapter Five

Imaging of the Adrenal Glands and Incidentaloma

[A] Imaging of the Adrenal Glands	150
I. Ultrasonography (US) of the Adrenal	150
II. Computerized Tomography (CT) Scanning of the Adrenals	154
III. Magnetic Resonance Imaging (MRI) of the Adrenals	160
IV. Nuclear Scanning	162
V. Adrenal Arteriography and Venography	167
[B] Adrenal Incidentaloma (Adrenaloma)	171
I. Prevalence	171
II. Functioning versus Nonfunctioning Incidentalomas	172
III. Benign versus Malignant Incidentalomas	173
IV. Fine-Needle Aspiration Biopsy of Incidentalomas	174
V. Policy for Management of Adrenal Incidentaloma	176

Chapter Six

Adrenal Surgery

[A] Open Adrenalectomy	180
I. Anterior Approach	180
II. Posterior Approach	186
VI. Flank (Lateral) Approach	190
VII. Thoracoabdominal Approach	193
[B] Laparoscopic Adrenalectomy	196
I. Transperitoneal Laparoscopic Adrenalectomy	196
II. Retroperitoneal Laparoscopic Adrenalectomy	207

Summary	213
----------------	------------

References	217
-------------------	------------

Arabic Summary	1
-----------------------	----------

List of Abbreviations

5-FU	5 Fluoro Uracil.
17 KS	17 Keto Steroid.
17-OHCS	17-Hydroxy Corticosteroid.
A II	Angiotensin II.
ACE	Angiotensin Converting Enzyme.
ACTH	Adreno Cortico Trophic Hormone.
ADH	Anti Diuretic Hormone.
ANF	Atrial Natruretic Factor.
APA	Aldosterone Producing Adenoma.
APUD	Amine Precursor Uptake & Decarboxylation.
cAMP	Cyclic Adenosine Monophosphate.
CBG	Cortisol Binding Globulin.
COMT	Catechol-O-Methyl Transferase.
CRH	Corticotropin-Releasing Hormone.
CT	Computerized Tomography.
DHEA	Dehydroepiandrosterone.
DHEAS	Dehydroepiandrosterone Sulfate.
DNA	Deoxy Ribonucleic Acid.
DNES	Diffuse Neuro-Endocrine System.
DOPA	Dihydroxy Phenylalanine.
EGF	Epidermal Growth Factor.
EGFr	Epidermal Growth Factor Receptor.
g	Gram.
GABA	Gamma-Amino Butyric Acid.
GH-RF	Growth Hormone Releasing Factor.
GIT	Gastro Intestinal Tract.
GN	Ganglioneuroma.
GNB	Ganglioneuroblastoma.
GSH	Glucocorticoid-Suppressible Hyperaldosteronsim.
HPF	High Power Field.
HVA	Homo Vanillic Acid.
IAH	Idiopathic Adrenocortical Hyperplasia.
IGF-I	Insulin like Growth Factor-I.
IRMA	Immuno Radio Metric Assay.
IVC	Inferior Vena Cava.
K	Potassium.
KI	Potassium Iodide.
LOH	Loss Of Heterozygosity.
MAO	Mono Amine Oxidase.
MEN	Multiple Endocrine Neoplasia.
MEN-I	Multiple Endocrine Neoplasia type I.
MEN-II	Multiple Endocrine Neoplasia type II.
MIBG	Meta Iodo-Benzyl-Guanedine.
MKI	Mitosis Karyorrhexis Index.
MR	Mitotic Rate.
MRI	Magnetic Resonance Imaging.
MSH	Melanocyte-Stimulating Hormone.
MTC	Medullary Thyroid Carcinoma.
Na	Sodium.
NB	Neuroblastoma.
NP-59	¹³¹ I-6-β-iodomethyl-19-norcholesterol.
NSE	Neuron Specific Enolase.
O, P'-DDD	[1,1 dichloro-2-(O-chlorophenyl)-2-(P-chlorophenyle) ethane], [Mitotane]
PNMT	Phenylethanolamine-N-Methyl Transferase.
POMC	Pro-Opio-Melano-Cortin.
PRA	Plasma Renin Activity.
RAAS	Renin-Angiotensin-Aldosterone-System.
RNA	Ribo Nucleic Acid.
SIADH	Syndrome of Inappropriate Anti Diuretic Hormone.
SIF	Small Intensely Flourescent cells.
SP-NB	Stroma Poor Neuroblastoma.
SR-NB	Stroma Rich Neuroblastoma.
TFF	Tumour Proliferation Fraction.
TSH	Thyroid Stimulating Hormone.
UFC	Urinary Free Cortisol.
VIP	Vasoactive Intestinal Peptide.
VMA	Vanillyl Mandelic Acid.

Introduction

The incidence of adrenal tumours is much lower than that of other tumours in humans, nevertheless, the rarity of these tumours should not belie their clinical significance because of their particular location and their particular endocrine effects. Correctly diagnosed and properly treated, most adrenal tumours are curable ; misdiagnosed or improperly managed, they can be fatal. With recent advances in imaging techniques and new methods of hormone determination, not only can the diagnosis of adrenal masses be accurate in patients with endocrine symptoms, but several "adrenal incidentalomas" may also be detected in patients with no symptoms. However dilemmas and controversies remain in the diagnosis and management of adrenal masses particularly incidentalomas (*Xiao et al, 1998*).

Abecassis et al reported the results of autopsy studies in 988 subjects, showing the incidence of unsuspected adenomas in the adrenal gland to be 1.9% (*Abecassis et al., 1985*).

This result agrees with the prevalence rate of 2% for adrenal masses detected incidentally by CT (*Ross and Aron, 1990*).

Classifying adrenal tumours as functional non-functional, based on their hormonal activity, is a significant guideline to the appropriate evaluation and management, although there are varied classifications of tumours in the adrenal gland according to anatomy, histology or pathology (*Xiao et al, 1998*).

Functional adrenal tumours usually present typical symptoms and signs because hormonal secretion is excessive. The diagnosis may be established from the clinical manifestations, hormonal measurements, and imaging in most patients. However such tumours may be overlooked in asymptomatic patients with adrenal masses possessing potential hormone secretion. The possibility of subclinical hormone production in such adrenal tumours is of interest (*Xiao et al, 1998*).

Phaeochromocytomas are the most frequently detected hormone-producing incidentaloma (*Xiao et al, 1998*).

Introduction

In a 50-year autopsy study (40078 autopsies) at the Mayo Clinic, Sutton et al described 41 patients with clinically unsuspected pheochromocytomas, of whom only 54% had a history of hypertension (*St. John Sutton et al, 1981*).

Pre-Cushing's syndrome and subclinical primary aldosteronism in incidentally discovered adrenal masses have also been reported (*Siren et al, 1993*).

In the asymptomatic patient, the minimal screening for hormonal activity consists of serum potassium level to evaluate aldosteronoma and a determination of urinary levels of VMA and catecholamines to exclude pheochromocytoma (*Xiao et al, 1998*).

A single dose 1mg overnight dexamethasone suppression test is recommended to screen for pre-Cushing's syndrome (*Cronin et al 1990*).

Recently adrenal scanning with ^{131}I -6- β -iodomethyl-19-norcholesterol (NP-59) was suggested to identify adrenal masses, because this compound is taken up by functional adrenal tumours, even in a subclinical level, but not by the suppressed contralateral gland (*Gross et al 1987*).

CT is better than MRI in detecting and localizing adrenal tumours, and MRI is more helpful than CT in distinguishing benign and malignant tumours, by comparing signal intensities and by contrast enhancement with Gadolinium. However, there remains an overlap of 20-30% between benign and malignant masses (*Krestin et al, 1991*).

Therefore fine-needle aspiration or core biopsy under U/S or CT guidance has been used to evaluate adrenal masses (*Katz et al, 1984*).

More recently, immunohistochemical staining techniques, chromosome karyotype analysis and gene investigations have been used to differentiate between malignant and benign adrenal masses (*Lin et al, 1994*).

Adrenal tumours may be treated surgically or therapeutically; removing the tumour by surgery is the only curative course. Surgery is principally indicated for functional adrenal tumours regardless of their characteristics;